NanoViricides completes Phase I clinical trial in India.

NanoViricides reports Phase I NV-387 clinical trial completed successfully in India, with data lock expected soon. The trial, approved for healthy and COVID-19 participants, was closed due to lack of suitable COVID-19 cases at trial sites despite a second site addition. The Company, a leader in antiviral nanomedicines, plans to analyze trial data to advance development of NV-387.

April 30, 2024
5 Articles

Further Reading